<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unipolar major depression with psychotic features: Maintenance treatment and course of illness</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unipolar major depression with psychotic features: Maintenance treatment and course of illness</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unipolar major depression with psychotic features: Maintenance treatment and course of illness</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony J Rothschild, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H86153761"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unipolar major depression with psychotic features is a severe subtype of unipolar major depression (major depressive disorder) [<a href="#rid1">1,2</a>]. The psychotic symptoms are delusions and/or hallucinations that are frequently consistent with depressive themes of guilt and worthlessness [<a href="#rid3">3</a>]. Psychotic depression and nonpsychotic depression differ in their diagnosis, treatment, and prognosis.</p><p>This topic reviews the maintenance treatment and prognosis of unipolar major depression with psychotic features. Acute treatment is discussed elsewhere, as are the epidemiology, pathogenesis, clinical features, assessment, and diagnosis of psychotic depression. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment"</a> and  <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4935653"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H2308758"><span class="h2">Unipolar major depression with psychotic features</span><span class="headingEndMark"> — </span>Unipolar major depression with psychotic features is characterized by an episode of unipolar major depression that includes delusions and/or hallucinations [<a href="#rid3">3</a>].</p><p>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode  (<a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">table 1</a>) and have no history of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 2</a>) or hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 3</a>) [<a href="#rid3">3</a>]. A major depressive episode is a two week or longer period with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, guilt, and recurrent thoughts about death or suicide. The clinical presentation and diagnosis of unipolar major depression are discussed further. (See  <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">"Unipolar depression in adults: Assessment and diagnosis"</a>.)</p><p>The primary distinction between unipolar major depression with psychotic features and unipolar major depression without psychotic features is that psychotic depression includes [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Delusions – False, fixed beliefs</p><p class="bulletIndent1"><span class="glyph">●</span>Hallucinations – False sensory perceptions, usually auditory</p><p></p><p>The clinical features, diagnosis, and differential diagnosis of unipolar major depression with psychotic features are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2308765"><span class="h2">Remission</span><span class="headingEndMark"> — </span>Remission is defined as the resolution of psychotic symptoms, and either resolution of depressive symptoms or improvement to the point that only one or two symptoms of mild intensity persist. Remission of unipolar psychotic depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Time to recovery'</a>.)</p><p class="headingAnchor" id="H129862897"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H92705313"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Maintenance treatment is indicated for unipolar psychotic depression because patients who remit are at high risk of suffering another episode of major depression, with or without psychotic features [<a href="#rid1">1,4,5</a>]. As an example, an observational study found that recurrence of major depression occurred in 74 percent of patients who remitted from an episode of unipolar psychotic depression [<a href="#rid1">1</a>]. However, there is relatively little high quality evidence to guide decisions about maintenance treatment.</p><p class="headingAnchor" id="H1751082723"><span class="h2">Choosing treatment</span><span class="headingEndMark"> — </span>Pharmacotherapy is generally used for maintenance treatment of unipolar psychotic depression. For acutely ill patients who remit with an antidepressant plus an antipsychotic, we usually maintain the same combination at the same dose for at least four to six months, at which point it may be feasible to gradually discontinue the antipsychotic while maintaining the antidepressant. However, it may be necessary to lower doses or switch the antidepressant and/or the antipsychotic because of side effects (eg, weight gain due to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>). Switching drugs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Duration of therapy and switching drugs'</a>.)</p><p>Patients with unipolar psychotic depression who remit with electroconvulsive therapy (ECT) are generally started on an antidepressant/antipsychotic combination [<a href="#rid6">6</a>]. The combination is started the day after ECT is completed, unless the patient is suffering cognitive impairment secondary to ECT, in which case maintenance pharmacotherapy is delayed until the impairment has dissipated. Choosing a combination is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Choosing a combination'</a>.)</p><p>However, maintenance ECT should be offered to patients who repeatedly remit with ECT and then relapse during maintenance combination pharmacotherapy. Maintenance ECT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Continuation and maintenance ECT'</a>.)</p><p class="headingAnchor" id="H57130950"><span class="h2">Duration and discontinuation</span><span class="headingEndMark"> — </span>During maintenance treatment of unipolar psychotic depression with combination pharmacotherapy, the antidepressant is generally maintained longer than the antipsychotic. Most authorities discontinue the antipsychotic after four to six months of sustained recovery from the episode of unipolar psychotic depression, and continue the antidepressant [<a href="#rid7">7-9</a>]. If the patient has side effects (eg, tardive dyskinesia with a first generation antipsychotic or weight gain with a second generation antipsychotic) and is clinically stable, it is reasonable to taper the antipsychotic sooner than four months. Conversely, for patients who relapsed while discontinuing the antipsychotic during maintenance treatment of prior episodes of psychotic depression, it is reasonable to maintain the antipsychotic for at least 6 to 12 months.</p><p>We suggest slowly tapering the antipsychotic over one month to increase the probability of detecting incipient depressive and psychotic symptoms before a full-blown episode of psychotic depression recurs [<a href="#rid10">10</a>]. Each week we taper by approximately 25 percent of the dose used to achieve remission. As an example, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> 20 mg/day is reduced each week by 5 mg/day. If symptoms recur during the taper, the dose is usually titrated back up to the full dose used initially to achieve remission. If a full-blown episode develops despite increasing the dose and does not improve within four to eight weeks, we suggest switching to an alternative antipsychotic. Switching drugs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Duration of therapy and switching drugs'</a>.)</p><p>For patients with unipolar psychotic depression who successfully taper and discontinue the antipsychotic, but subsequently relapse during maintenance treatment with antidepressant monotherapy, we suggest restarting the antipsychotic that was discontinued. The relapse is treated as a new acute episode; acute treatment is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Treatment'</a>.)</p><p>We suggest maintenance treatment with an antidepressant for a minimum of two years and as long as the patient’s lifetime, consistent with practice guidelines from the Canadian Network for Mood and Anxiety Treatments [<a href="#rid4">4</a>]. The duration of maintenance treatment depends upon clinical factors and is generally longer in patients with [<a href="#rid11">11,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Residual symptoms, particularly suicidal ideation</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing comorbid psychopathology</p><p class="bulletIndent1"><span class="glyph">●</span>Psychosocial stressors</p><p class="bulletIndent1"><span class="glyph">●</span>A history of suicide attempts</p><p class="bulletIndent1"><span class="glyph">●</span>A greater number of prior major depressive episodes</p><p class="bulletIndent1"><span class="glyph">●</span>A history of longer or more severe (eg, psychotic) depressive episodes</p><p class="bulletIndent1"><span class="glyph">●</span>An early age of onset of unipolar major depression</p><p></p><p>For patients who decide to discontinue their antidepressant, we suggest tapering it over two months to increase the probability of detecting incipient depressive and psychotic symptoms before a full-blown episode of psychotic depression recurs. Every other week we taper by approximately 25 percent of the dose used to achieve remission. As an example, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> 200 mg/day is reduced every other week by 50 mg/day.</p><p>If depressive symptoms recur during the antidepressant taper, the antidepressant dose is generally titrated back up to the full dose used initially to achieve remission. If psychotic symptoms also recur during the antidepressant taper, the antidepressant dose is titrated back up to the full dose, and the previously used antipsychotic is restarted and titrated up. If a full-blown psychotic depressive episode develops despite increasing the antidepressant dose and resuming the antipsychotic, and does not improve within four to eight weeks, we suggest switching to an alternative antidepressant/antipsychotic combination. Switching drugs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Duration of therapy and switching drugs'</a>.)</p><p>For patients with unipolar psychotic depression who successfully taper and discontinue both the antipsychotic and antidepressant, but subsequently relapse, we suggest restarting the same combination that was discontinued. The relapse is treated as a new acute episode; acute treatment is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H87479261"><span class="h2">Monitoring the patient</span><span class="headingEndMark"> — </span>Patients with unipolar psychotic depression who remit should be regularly interviewed and monitored for recurrence of depressive and psychotic symptoms. Particular attention is given to suicidal ideation that includes a plan, and to psychotic symptoms that place the patient at imminent risk of coming to harm (eg, auditory hallucinations commanding the patient to kill herself). Patients with psychotic depression can be monitored with the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpsychoticdepressionassessmentscale.com%2F&amp;token=V1h9NYzhXjsCSLU4gvnwgxcrssWxKVP9ZlSA7%2BQx6TkTQSjqKp1E1XtYcAIhvj5ihoT%2BXIOtI8WHecX%2BRqmodQ%3D%3D&amp;TOPIC_ID=16596" target="_blank">Psychotic Depression Assessment Scale</a>, which is a clinically valid, 11-item, clinician-administered instrument [<a href="#rid13">13,14</a>]. The scale consists of the six-item melancholia subscale of the Hamilton Depression Rating Scale and five psychosis items from the Brief Psychiatric Rating Scale. The use of scales to monitor symptoms of depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)"</a>.)</p><p>For patients with unipolar psychotic depression who remit and remain stable, monitoring can be tapered, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the time of remission can be seen every two weeks for one or two more visits, then monthly for one to three visits, then every two months for one to three visits, and then every three to six months. More frequent visits should be scheduled for patients who develop depressive or psychotic symptoms; monitoring acutely ill patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">"Unipolar major depression with psychotic features: Acute treatment", section on 'General principles'</a>.)</p><p class="headingAnchor" id="H2308799"><span class="h2">Evidence of efficacy</span><span class="headingEndMark"> — </span>For patients who recover from an episode of unipolar major depression with psychotic features, the best evidence indicates that maintenance treatment with an antidepressant plus an antipsychotic is superior to an antidepressant alone. In one study, patients acutely ill with unipolar psychotic depression were treated with open-label <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> (median dose 150 mg/day) plus <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (median dose 15 mg/day) for up to 12 weeks [<a href="#rid10">10,15</a>]. Patients who achieved remission of their psychotic features, and whose depression either remitted or nearly remitted, continued treatment with open-label sertraline plus olanzapine for eight weeks; near remission was defined as reduction of baseline depressive symptoms ≥50 percent, along with a rating of much or very much improved. At the end of the eight weeks, patients (n = 126) who continued to meet criteria for remission or near remission continued to receive open-label sertraline, and were randomly assigned to double-blind olanzapine or placebo for 36 weeks. Patients assigned to placebo were switched (cross-tapered) from olanzapine to placebo over four weeks. The results during the randomized treatment phase included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The primary outcome was relapse, which was defined as one or more of the following: reoccurrence of major depression and/or psychosis, having a suicide plan, attempting suicide, or admission to an inpatient psychiatric unit. Relapse occurred in fewer patients treated with <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> plus <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> than sertraline plus placebo (20 versus 55 percent, hazard ratio 0.25, 95% CI 0.13-0.48). In addition, the number of patients with a psychotic relapse was three times smaller with olanzapine than placebo (6 and 19 percent [4/64 and 12/62]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain was greater with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> – Olanzapine caused a mean weight gain of 2.6 kg (5.7 lb), whereas placebo caused a mean weight loss of 1.4 kg (3.1 lb). (The weight gain with olanzapine during randomized treatment was in addition to the 5.4 kg [12 lb] weight gain that occurred during open-label treatment with olanzapine.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increase in waist circumference was greater with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> – Olanzapine caused a mean increase in waist circumference of 1.5 cm (0.6 in), whereas placebo caused a mean decrease of 2.0 cm (0.8 in).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parkinsonism was greater with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> than placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One or more falls occurred in roughly twice as many patients who received <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> than placebo (31 and 18 percent).</p><p></p><p class="headingAnchor" id="H4936027"><span class="h1">COURSE OF ILLNESS</span><span class="headingEndMark"> — </span>Unipolar major depression with psychotic features is associated with more recurrences of major depression (with or without psychotic features) and a higher mortality rate, compared with unipolar nonpsychotic depression [<a href="#rid16">16</a>].</p><p>Most patients with unipolar psychotic depression suffer multiple recurrences of major depression either with or without psychotic features [<a href="#rid17">17</a>]. Observational studies show that the median time to recurrence may be as long 2.6 years after recovery from the first lifetime episode of psychotic depression [<a href="#rid18">18</a>], and as short as 26 weeks in patients who have a history of multiple depressive episodes [<a href="#rid19">19</a>].</p><p>In addition, patients who recover from unipolar psychotic depression are more likely to suffer a recurrence of major depression than are patients who recover from unipolar nonpsychotic depression [<a href="#rid12">12,20-24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A one-year, community survey of 114 patients with unipolar psychotic depression and 662 patients with unipolar nonpsychotic depression found that recurrence of major depression occurred in more patients with psychotic depression than nonpsychotic depression (74 versus 62 percent) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A two-year, observational study of 87 patients with unipolar psychotic depression found that recurrence of major depression was greater for patients who remitted from psychotic depression compared with patients who remitted from nonpsychotic depression (47 versus 15 percent) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A six-year observational study of 1053 patients with unipolar psychotic depression and 1315 patients with unipolar nonpsychotic depression examined rehospitalization after first lifetime admission; readmission occurred sooner for patients with psychotic depression (2.6 versus 3.6 years) [<a href="#rid18">18</a>].</p><p></p><p>The higher rate of recurrence in psychotic depression compared with nonpsychotic depression is probably responsible for the greater disability and use of services in patients with psychotic depression [<a href="#rid19">19,21,25</a>].</p><p>Patients who recover from an episode of unipolar psychotic depression are often psychotic during subsequent recurrences of major depression [<a href="#rid2">2,17,23</a>], and the delusional content may be consistent from one episode of psychotic depression to the next [<a href="#rid26">26</a>]. In addition, the risk of psychotic features during a recurrent episode of major depression is higher in patients who recover from psychotic depression compared with patients who recover from nonpsychotic depression [<a href="#rid17">17,27</a>].</p><p class="headingAnchor" id="H86150169"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Unipolar major depression is associated with increased all-cause mortality compared with the general population [<a href="#rid28">28</a>], and mortality also appears to be greater for psychotic depression than nonpsychotic depression [<a href="#rid29">29</a>]. As an example, an 18-year national registry study compared all-cause mortality in patients with first-episode psychotic depression (n &gt;19,000) or severe nonpsychotic depression (n &gt;90,000) [<a href="#rid30">30</a>]. After adjusting for potential confounding factors (eg, age at initial diagnosis and comorbid psychiatric and general medical disorders), the analyses found that the risk of death was 40 percent greater in psychotic depression (hazard ratio 1.4, 95% CI 1.3-1.5). The risk was highest in the first year after the initial diagnosis of psychotic depression, and more than half the deaths occurred within five years of the initial diagnosis. Psychotic depression was associated with elevated mortality due to suicide and death from accidents and cardiovascular diseases.</p><p>Suicidal ideation and suicide attempts in patients with unipolar psychotic depression are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis", section on 'Suicidality'</a>.)</p><p class="headingAnchor" id="H2097286253"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H86154919"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Unipolar major depression with psychotic features is characterized by an episode of unipolar major depression that includes delusions and/or hallucinations. A major depressive episode is a two week or longer period with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, guilt, and recurrent thoughts about death or suicide  (<a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">table 1</a>). (See <a class="local">'Definitions'</a> above and  <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unipolar major depression with psychotic features is a highly recurrent illness. For patients with unipolar psychotic depression that remits, we suggest initial maintenance treatment with the antidepressant and antipsychotic combination that achieved remission, rather than discontinuing the antipsychotic and using antidepressant monotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For acute and maintenance treatment, we frequently use <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> as the antidepressant and nearly always use <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> as the antipsychotic.</p><p></p><p class="bulletIndent1">The antipsychotic is generally tapered and discontinued after sustained recovery for four to six months, and the antidepressant is maintained for at least two years. Maintenance ECT is a reasonable option for patients who fail multiple courses of maintenance pharmacotherapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with unipolar psychotic depression, the median time to recurrence of major depression (with or without psychotic features) may be as long 2.6 years after recovery from the first lifetime episode of psychotic depression, and as short as 26 weeks in patients who recover from psychotic depression and have a history of multiple depressive episodes. (See <a class="local">'Course of illness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All-cause mortality appears to be greater for unipolar psychotic depression than nonpsychotic depression. (See <a class="local">'Mortality'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991; 48:1075.</a></li><li><a class="nounderline abstract_t">Nelson JC, Bickford D, Delucchi K, et al. Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-Analysis. Am J Psychiatry 2018; 175:897.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li><a class="nounderline abstract_t">Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.</a></li><li><a class="nounderline abstract_t">Aronson TA, Shukla S, Hoff A. Continuation Therapy After ECT for Delusional Depression: A Naturalistic Study of Prophylactic Treatments and Relapse. Convuls Ther 1987; 3:251.</a></li><li><a class="nounderline abstract_t">Patel DA, Flint AJ, Rothschild AJ, et al. Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. J Clin Psychopharmacol 2021; 41:196.</a></li><li><a class="nounderline abstract_t">Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry 2003; 64:390.</a></li><li><a class="nounderline abstract_t">Wijkstra J, Burger H, van den Broek WW, et al. Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord 2010; 123:238.</a></li><li><a class="nounderline abstract_t">Flint AJ, Rifat SL. Two-year outcome of psychotic depression in late life. Am J Psychiatry 1998; 155:178.</a></li><li><a class="nounderline abstract_t">Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA 2019; 322:622.</a></li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice guideline for the treatment of major depressive disorder, third edition. Am J Psychiatry 2010; 167:10.</a></li><li class="breakAll">American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).</li><li><a class="nounderline abstract_t">Østergaard SD, Meyers BS, Flint AJ, et al. Measuring psychotic depression. Acta Psychiatr Scand 2014; 129:211.</a></li><li><a class="nounderline abstract_t">Østergaard SD, Pedersen CH, Uggerby P, et al. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord 2015; 173:261.</a></li><li><a class="nounderline abstract_t">Coryell WH. Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges. JAMA 2019; 322:615.</a></li><li><a class="nounderline abstract_t">Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull 2013; 39:787.</a></li><li><a class="nounderline abstract_t">Coryell W, Winokur G, Shea T, et al. The long-term stability of depressive subtypes. Am J Psychiatry 1994; 151:199.</a></li><li><a class="nounderline abstract_t">Kessing LV. Subtypes of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Psychopathology 2003; 36:285.</a></li><li><a class="nounderline abstract_t">Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry 1996; 153:483.</a></li><li><a class="nounderline abstract_t">Prudic J, Olfson M, Marcus SC, et al. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004; 55:301.</a></li><li><a class="nounderline abstract_t">Coryell W, Zimmerman M, Pfohl B. Outcome at discharge and six months in major depression. The significance of psychotic features. J Nerv Ment Dis 1986; 174:92.</a></li><li><a class="nounderline abstract_t">Aronson TA, Shukla S, Hoff A, Cook B. Proposed delusional depression subtypes: preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord 1988; 14:69.</a></li><li><a class="nounderline abstract_t">Helms PM, Smith RE. Recurrent psychotic depression. Evidence of diagnostic stability. J Affect Disord 1983; 5:51.</a></li><li><a class="nounderline abstract_t">Spiker DG, Stein J, Rich CL. Delusional Depression and Electroconvulsive Therapy: One Year Later. Convuls Ther 1985; 1:167.</a></li><li><a class="nounderline abstract_t">Rothschild AJ, Schatzberg AF. Psychotic Depression: A newly recognized subtype. Clin Neurosci 1993; 1:75.</a></li><li><a class="nounderline abstract_t">Lykouras E, Christodoulou GN, Malliaras D. Type and content of delusions in unipolar psychotic depression. J Affect Disord 1985; 9:249.</a></li><li><a class="nounderline abstract_t">Gournellis R, Lykouras L, Fortos A, et al. Psychotic (delusional) major depression in late life: a clinical study. Int J Geriatr Psychiatry 2001; 16:1085.</a></li><li><a class="nounderline abstract_t">Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.</a></li><li><a class="nounderline abstract_t">Vythilingam M, Chen J, Bremner JD, et al. Psychotic depression and mortality. Am J Psychiatry 2003; 160:574.</a></li><li><a class="nounderline abstract_t">Paljärvi T, Tiihonen J, Lähteenvuo M, et al. Mortality in psychotic depression: 18-year follow-up study. Br J Psychiatry 2023; 222:37.</a></li></ol></div><div id="topicVersionRevision">Topic 16596 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1845225" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The validity of major depression with psychotic features based on a community study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792050" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29792050" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19674794" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940926" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Continuation Therapy After ECT for Delusional Depression: A Naturalistic Study of Prophylactic Treatments and Relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33587400" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716238" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : How long should patients with psychotic depression stay on the antipsychotic medication?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880189" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term response to successful acute pharmacological treatment of psychotic depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9464195" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Two-year outcome of psychotic depression in late life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31429896" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Practice guideline for the treatment of major depressive disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Practice guideline for the treatment of major depressive disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799875" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Measuring psychotic depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25462426" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical and psychometric validation of the psychotic depression assessment scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31429877" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23599251" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Challenges in the treatment of major depressive disorder with psychotic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The long-term stability of depressive subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14646451" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Subtypes of depressive episodes according to ICD-10: prediction of risk of relapse and suicide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8599395" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Importance of psychotic features to long-term course in major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744473" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness of electroconvulsive therapy in community settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944599" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outcome at discharge and six months in major depression. The significance of psychotic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2892870" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Proposed delusional depression subtypes: preliminary evidence from a retrospective study of phenomenology and treatment course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6220044" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recurrent psychotic depression. Evidence of diagnostic stability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940820" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Delusional Depression and Electroconvulsive Therapy: One Year Later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Psychotic Depression: A newly recognized subtype</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2934458" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Type and content of delusions in unipolar psychotic depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11746655" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Psychotic (delusional) major depression in late life: a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063145" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mortality of patients with mood disorders: follow-up over 34-38 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12611843" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Psychotic depression and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36250518" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mortality in psychotic depression: 18-year follow-up study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
